교수진 소개 │ 교육 │ GCSP

교수진

교수진 소개

Yuri CHO, MD, Ph.D.

Name: Yuri CHO, MD, Ph.D.
Faculty Appointment: (title, department): Assistant Professor, Department of Cancer Biomedical Science
Staff physician, National Cancer Center Hospital Research Scientist, Research Institute
Area of Expertise: Hepatology
Contact no: +82-31-920-1680
E-mail: yuricho@ncc.re.kr

Work Experience: Mar 2021 – : Staff Physician / Research Scientist, National Cancer Center
Mar 2016 – Sep 2021: Assistant Professor, CHA University
Mar 2013 – Feb 2016: Clinical Fellow, Seoul National University Hospital
Educational Background: ar 2014 – Feb 2017: Ph.D. Seoul National University
Mar 2012 – Feb 2014: M.S. Seoul National University
Mar 2002 – Feb 2008: M.D. Seoul National University
Research Interests: Novel therapeutic approaches for hepatocellular carcinoma & chronic hepatitis B
Mechanistic studies of chemotherapy resistance
Clinical trials
Achievements: 1. Cho Y, Lee DH, Oh HS, Seo JY, Lee DH, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jung HC, Yoon YB, Song IS. Higher prevalence of obesity in gastric cardia adenocarcinoma compared to gastric non-cardia adenocarcinoma. Dig Dis Sci. 2012 Oct;57(10):2687-92

2. Cho Y, Lee DH, Chung KH, Jin E, Lee JH, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon JH, Lee HS, Kim CY, Kim YJ. The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. Dig Dis Sci. 2013 May;58(5):1363-70.

3. Lee JH, Cho Y (co-first), Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH, Lee HS, Kim YJ. Prior exposure to lamivudine increases entecavir-resistance risk in chronic hepatitis B patients without detectable lamivudine-resistance. Antimicrob Agents Chemother. 2014 Mar;58(3):1730-7

4. Cho Y, Park SY, Lee JH, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yoon JW, Kwon JH, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. J Clin Gastroenterol. 2014 May-Jun;48(5):444-9.

5. Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography computed tomography have role in initial staging of hepatocellular carcinoma? PLoS One. 2014 Aug ;9(8):e105679.

6. Cho Y, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ. Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. J Med Virol. 2015 Jun;87(6):999-1007.

7. Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm Sin B. 2015;5(6):544–553

8. Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Sofosbuvir-based therapy for the patients with chronic hepatitis C: Early experience in Korea providing its efficacy and safety. Clin Mol Hepatol. 2015 Dec;21(4):358-64.

9. Lee JH, Cho Y (co-first), Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, L Teperman, J Park, Kim YJ, Suh KS, Yoon JH. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016 May;263(5):842-50.

10. Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH. High titers of anti-HBs prevent rituximab related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. J Med Virol. 2016 Jun;88(6):1010-7.

11. Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon JH. Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating galectin-14. PLoS One. 2016 Aug 5;11(8):e0160822.

12. Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Hypoxia enhances tumor-stroma crosstalk that drives the progression of hepatocellular carcinoma. Dig Dis Sci. 2016 Sep;61(9):2568-77.

13. Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomed Pharmacother. 2016 Oct;83:607-616.

14. Cho Y, Sinn DH, Yu SJ, Gwak GY, Kim JH, Yoo YJ, Jeon DW, Kim TY, Lee HY, Cho EJ, Lee JH, Kim YJ, and Yoon JH. Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B. PLoS One. 2016 Nov 15;11(11):e0165722.

15. Cho Y, Lee J-H, Lee DH, Cho EJ, Yu SJ, Yi N-J, Lee K-W, Kim YJ, Yoon J-H, Suh K-S. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget. 2017 Jul 18;8(29):47555-47564.

16. Lee JY, Cho Y (co-first), Hong MH, Kim J, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W Incidence, inhospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide study. J Gastroenterol Hepatol. 2019 Apr;34(4):747-754.

17. Cho Y, Park YS, Kim HW, Kim W, Lee HJ, Kim DJ. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Trials. 2018 Dec 22;19(1):696.

18. Cho Y, Han J, Kim W, Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. J Liver Cancer 2019;19(1):1-11

19. Park TH, Chong Y, Park MJ, Cho Y (co-corresponding). PARP1 inhibition as a novel therapeutic target of keloid disease. Adv Wound Care (New Rochelle). 2019 May 1;8(5):186-194.

20. Kang JA, Kim SW, Park MJ, Park HJ, Kim JH, Park SH, Hwang JR, Kim YC, Kim YJ, Cho Y (co-corresponding), Jin MS, Park SG. Ciclopirox inhibits hepatitis B virus secretion by blocking capsid assembly. Nat Commun. 2019 May 16;10(1):2184.

21. Cho Y, Lim SK, Joo SK, Jeong DH, Kim JH, Bae JM, Park JH, Chang MS, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm. Liver Int. 2019 Sep;39(9):1722-1731.

22. CY, Cho Y (co-first), Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joe JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Study. Cancers (Basel). 2019 Sep 3;11(9).

23. Cho Y, Kim W. Reply to: Influence of Helicobacter pylori-connected metabolic syndrome on nonalcoholic fatty liver disease and its related colorectal neoplasm high risk. Liver Int. 2020 Feb;40(2):476-477.

24. Cho Y, Park MJ, Kim K, Park JY, Kim J, Kim W, Yoon JH. Tumor-stroma crosstalk enhances REG3A expressions that drive the progression of hepatocellular carcinoma. Int. J. Mol. Sci. 2020 Jan 11;21(2). pii: E472.

25. Cho Y, Choi YI, Oh S, Han J, Joo SK, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease. Hepatol Int. 2020;14:270-280.

26. Cho Y, Park MJ, Kim K, Kim SW, Kim W, Oh S, Lee J. Reactive oxygen species-induced activation of YAP-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2020 Nov 14;26(42):6599-6613. doi: 10.3748/wjg.v26.i42.6599.

27. Kang SH, Cho Y (co-first), Jeong SW, Kim SU, Lee JW: On behalf of Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol. 2021 Mar 22. doi: 10.3350/cmh.2021.0067. Online ahead of print.

28. Cho Y, Cho EJ, Yoo JJ, Chang Y, Chung GE, Jeong SM, Park SH, Han K, Shin DW, Yu SJ. Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers. 2021, 13, 1599. doi.org/10.3390/cancers13071599

29. Jeong S, Cho Y (co-first), Park SM, Kim W. Differential effectiveness of tenofovir and entecavir for prophylaxis of hepatocellular carcinoma in chronic hepatitis B patients depending on coexisting cirrhosis and prior exposure to antiviral therapy: A systematic review and meta-analysis. J Clin Gastroenterol. 2021 Apr 21. doi: 10.1097/MCG.0000000000001548. Online ahead of print.

30. Kim WC, Kang JA, Park M, Jeong PH, Kim YJ, Cho Y (co-corresponding), Park SG, Kim YC. Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents. J Med Chem. 2021 Apr 22. doi: 10.1021/acs.jmedchem.0c01938. Online ahead of print.

31. Kim MA, Lee YJ, Yoon JS, Lee MJ, Kye SS, Kim SW, Cho Y (co-corresponding). The FIB-4 index is a useful predictor for the development of hepatocellular carcinoma in patients with coexisting nonalcoholic fatty liver disease and chronic hepatitis. Cancers 2021, 13, 2301. doi.org/10.3390/cancers13102301

32. Kang SH, Lee HW, Yoo JJ, Cho Y (co-first), Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021 Jun 22. doi: 10.3350/cmh.2021.0178. Online ahead of print.

33. Kim TS, Lee M, Shim MS, Park M, Lee CY, Choi DH, Cho Y(co-corresponding). Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1. Int. J. Mol. Sci. 2021 Sep 17;22(18):10027. doi: 10.3390/ijms221810027.

34. Kim SW, Yoon JS, Lee M, Cho Y. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol. 2022;28(1):17-30.

35. Choi SI, Cho Y (co-first), Ki M, Kim BH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Hong EK, Kim CM, Park JW. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS One. 2022 Mar 24;17(3):e0265668. doi: 10.1371/journal.pone.0265668. eCollection 2022.

36. Cho Y, Cho EJ, Yoo JJ, Chang Y, Chung GE, Choi IY, Park SH, Han K, Kim YJ, Yoon JH, Shin DW, Yu SJ. The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. Front Oncol. 2022 May 4;12:863352. doi: 10.3389/fonc.2022.863352. eCollection 2022.

37. Lee D, Kang JA, Lim C, Bae S, Choi J, Park M, Kim YC, Cho Y(co-corresponding), Park SG, Seo J. Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation. Bioorg Med Chem. 2022 Aug 15;68:116862. doi: 10.1016/j.bmc.2022.116862. Epub 2022 Jun 6. PMID: 35691131

38. Cho Y, Kim BH, Park JW. The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea. Clin Mol Hepatol. 2023 Jan;29(1):99-101. doi: 10.3350/cmh.2022.0321. Epub 2022 Oct 27.

39. Cho Y, Kim BH, Park JW. Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma. Clin Mol Hepatol. 2023 Feb;29(Suppl):S220-S227.

40. Cho Y, Kim BH, Kim TH, Koh YH, Park JW. A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment. J Liver Cancer. 2023 Mar;23(1):206-212. doi: 10.17998/jlc.2023.02.09.

41. Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clin Mol Hepatol. 2023 Apr;29(2):252-262.

42. Hur MH, Cho Y (co-first), Kim DY, Lee JS, Kim GM, Kim HC, Sinn DH, Hyun D, Lee HA, Seo YS, Lee IJ, Park JW, Kim YJ. Transarterial Radioembolization versus Tyrosine Kinase Inhibitor in Hepatocellular Carcinoma with Portal Vein Thrombosis. Clin Mol Hepatol. 2023 May 30. doi: 10.3350/cmh.2023.0076. Online ahead of print.

43. Cho Y, Choi JW, Kwon H, Kim KY, Lee BC, Chu HH, Lee DH, Lee HA, Kim GM, Oh JS, Hyun D, Lee IJ, Rhim H; Research Committee of the Korean Liver Cancer Association. Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association. Korean J Radiol. 2023 Jul;24(7):606-625. doi: 10.3348/kjr.2023.0385.

44. Cho Y, Park S, Park S, Choi W, Kim B, Han H. Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea. Infect Dis Ther. 2023 Oct;12(10):2387-2403. doi: 10.1007/s40121-023-00860-8.

45. Cho Y, Kim BH, Lim YS. Recent Hepatocellular carcinoma Managements in Korea: Focus on the updated guidelines in 2022. Digestive Disease Interventions. 2024